Thomas Waldmann, M.D.
Co-Chief, Lymphoid Malignancies Branch - NCI NIH
Thomas A. Waldmann, M.D. received his M.D. from Harvard Medical School. He joined the NCI in 1956, and has been Chief of Metabolism Branch since 1973. Over his 59-year career he defined the IL-2 receptor subunits, IL-2R beta and IL-2R alpha using the first-ever reported anti-cytokine receptor monoclonal antibody (anti-Tac, daclizumab, Zenapax). These studies culminated in the definition of the IL-2 receptor as an exceptionally valuable target for monoclonal antibody mediated therapy of leukemia, lymphoma, and multiple sclerosis. He co-discovered IL-15, elucidated its role in persistence of NK and CD8 memory T- cells and completed the first in-human trial of IL-15 in patients with metastatic malignancy. He introduced blockade of the IL-15/IL-15 receptor and its Jak/STAT signaling pathway for leukemias and autoimmune diseases where gamma-c cytokines including IL-15 play a pathogenic role. His honors include: the Ehrlich Medal, Abbott Laboratories Prize, Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research, Milken Family Medical Foundation Distinguished Basic Scientist Award, Artois-Baillet Latour Health Prize, AAI-Dana Foundation Award in Human Immunology Research and election to the National Academy of Sciences, The SAMMIE Life Time Achievement Award, identification as an NIH Distinguished Investigator, American Academy of Arts and Sciences, Institute of Medicine of the National Academy of Sciences and Royal Society of the Medical Sciences (UK).